Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight

Summary

Market analysis article discussing the hypertrophic cardiomyopathy market transformation driven by emerging targeted therapies including Lexicon Pharmaceuticals' Sotagliflozin (ZYNQUISTA) and other disease-modifying agents as alternatives to conventional treatments.